Hasil Pencarian - "Essex"

  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128

    Multi-Criteria Decision Analysis to Develop an Efficacy-Safety Profile of Parenteral Analgesics Used in the Treatment of Postoperative Pain oleh Schug S, Pogatzki-Zahn E, Phillips LD, Essex MN, Xia F, Reader AJ, Pawinski R

    Diterbitkan 2020-08-01
    "…Stephan Schug,1,2 Esther Pogatzki-Zahn,3 Lawrence D Phillips,4 Margaret Noyes Essex,5 Feng Xia,5 Alison J Reader,6 Robert Pawinski6 1Discipline of Anaesthesiology and Pain Medicine, Medical School, University of Western Australia, Perth, WA, Australia; 2Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, WA, Australia; 3Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Muenster, Muenster, Germany; 4Department of Management, London School of Economics and Political Science, London, UK; 5Pfizer Inc, New York, NY, USA; 6Pfizer Ltd, Walton Oaks, Tadworth, UKCorrespondence: Margaret Noyes Essex Tel +1 212 733 8018Fax +1 646 441 5967Email margaret.essex@pfizer.comBackground: Identifying the optimal treatment in an acute postoperative setting remains a challenge. …"
    Dapatkan teks lengkap
    Artikel
  9. 129

    Children’s International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis oleh Burke CA, Phillips R, Berger MF, Li C, Essex MN, Iorga D, Lynch PM

    Diterbitkan 2017-07-01
    "…Carol A Burke,1 Robin Phillips,2 Manuela F Berger,3 Chunming Li,3 Margaret Noyes Essex,4 Dinu Iorga,3 Patrick M Lynch5 1Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA; 2Department of Surgery, St Mark’s Hospital and Academic Institute, Middlesex, UK; 3Global Clinical Affairs, 4Global Medical Affairs, Pfizer Inc., New York, NY, 5Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Objective: To evaluate the efficacy and safety of celecoxib versus placebo in the prevention and treatment of colorectal polyposis in children with familial adenomatous polyposis (FAP).Methods: In this Phase III, double-blind, randomized, placebo-controlled, multicenter trial patients aged 10–17 years with FAP were randomized to celecoxib (16 mg/kg/day) or placebo for up to 5 years. …"
    Dapatkan teks lengkap
    Artikel
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140